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Alterations in the size of microsatellite DNA sequences, namely
microsatellite instability (MSI), have been demonstrated in a
subset of gastrointestinal carcinomas (Aaltonen et al, 1993; Han 
et al, 1993; Ionov et al, 1993; Thibodeau et al, 1993). MSI results
from the inactivation of DNA mismatch repair (MMR) genes. The
defective MMR system does not correct the heteroduplex DNA
formed due to slippage-induced replication errors, and insertions
and deletions of repeat units occur after subsequent replication
(Strand et al, 1993). Among the MMR genes, the inactivation of
hMSH2 and hMLH1 genes are most frequently observed in
colorectal carcinomas with MSI (Kinzler and Vogelstein, 1996;
Thibodeau et al, 1996; Peltomaki et al, 1997). Recent studies
demonstrated frequent hMLH1 gene inactivation in the tumours
with MSI and most of the inactivation was related to the methyl-
ation of the hMLH1 promoter (Kane et al, 1997; Cunningham et al,
1998). 
Gastric adenoma is a precancerous lesion and a subset of gastric
adenomas show MSI (Tamura et al, 1995; Semba et al, 1996; Kim
et al, 1999). We and others have previously reported that the inci-
dence of MSI in gastric adenomas was similar to that of gastric
carcinomas, however the frameshift mutations at the coding
mononucleotide repeats were confined to several genes and the
mutational rate was much lower in the MSI positive gastric
adenomas (Kim et al, 1999). Frequent inactivation of the hMLH1
gene by promoter methylation has been reported in MSI-positive
gastric carcinomas (Fleischer et al, 1999; Leung et al, 1999), but
the origin of MSI in gastric adenomas has not been characterized.
In this study, we performed an immunohistochemical study for the
two mismatch repair genes, hMSH2 and hMLH1, and examination
of the hMLH1 gene promoter methylation on gastric adenomas
with or without MSI and compared the results with that of gastric
carcinomas. Our results demonstrate that MSI in gastric adenomas
originates from inactivation of hMLH1 by promoter methylation. 
MATERIALS AND METHODS 
Patients and tissue samples 
In total, 86 cases histologically confirmed as gastric adenoma and
38 gastric carcinomas were included in this study. Among them,
56 gastric adenomas and 18 gastric carcinomas had been analysed
previously for MSI status and frameshift mutation of the target
genes (Kim et al, 1999). All the adenoma cases were identified in
the Department of Pathology at Yonsei University Medical Center
between September 1995 and February 2000. All cases were
examined by 3 pathologists (HKa, SEK and HKi) without know-
ledge of the molecular data. Among the 86 gastric adenomas, 16
cases had separate synchronous carcinoma and 7 cases had
multiple synchronous adenomas. The 16 MSI-positive gastric
carcinomas and 22 MSI-negative carcinomas were selected for
comparison from the ongoing study of 113 cases. DNAs were
extracted from tissue sections from surgical specimens that had
been fixed in formalin and embedded in paraffin for routine
histopathological examination. To enrich the tumour cell popula-
tion, sections with more than 70% of tumour cell areas were
selected from the haematoxylin-eosin-stained slides and isolated
by microdissection. 
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DNAs from gastric tumours and paired normal DNAs were PCR
amplified at 5 microsatellite loci (BAT26, BAT25, D2S123,
D5S346, and D17S250) to evaluate the MSI (Boland et al, 1998).
PCR reactions were carried out as described previously (Kim et al,
1999). MSI was determined by the mobility shift of products from
PCR. Based on the number of markers displaying instability per
tumour, cases showing MSI in two or more markers were classi-
fied as MSI-positive and the rest of the cases were classified as
MSI-negative (Figure 1A). 
Frameshift mutation analysis of the target genes 
Frameshift mutations of the 5 target genes (the region comprising
the (A) 10 tract in the TGF-β RII gene, (G)8 tract in the BAX gene,
(A)8 tract of the hMSH3 gene, (C)8 tract of the hMSH6 gene and
(G)8 tract of the IGFIIR gene) in our 15 cases of MSI-positive
gastric adenomas and 16 cases of MSI-positive gastric carcinomas
were analysed by PCR amplification as described previously (Kim
et al, 1999). 
Immunohistochemical analysis of hMLH1 and hMSH2 
Formalin-fixed and paraffin-embedded tissues were used for the
immunostaining of hMLH1 and hMSH2. Deparaffinization and
rehydration were performed using xylene and alcohol. The
sections were treated with 0.3% hydrogen peroxidase for 3 min
and blocking antibody for 30 min. Mouse monoclonal antibodies
against hMLH1 protein (clone G168-728, PharMingen, San
Diego, CA) and hMSH2 protein (clone G219-1129, PharMingen)
were used in combination with antigen retrieval in a citrate buffer.
Avidin–biotin complex methodology was employed. The chro-
mogen was diaminobenzidine and counterstaining was done with
haematoxylin. The evaluation of hMSH2 and hMLH1 gene
product expression was categorized as positive, decreased or nega-
tive (Figure 2). Cases with definite nuclear staining in more than
30% of the tumour cells were categorized as positive, cases with
definite nuclear staining in less than 30% of the tumour cells were
categorized as decreased and cases with complete absence of
nuclear staining were categorized as negative. 
Methylation analysis of hMLH1 gene 
We investigated the status of hMLH1-promoter region in 35 
gastric adenomas (15 MSI-positive gastric adenomas and 20 MSI-
negative gastric adenomas) and 38 gastric carcinomas (16 MSI-positive
gastric carcinomas and 22 MSI-negative gastric carcinomas).
DNA methylation patterns in the promoter region of hMLH1 gene
were determined by chemical modification of unmethylated DNA
and subsequent PCR using primers specific for either methylated
or modified unmethylated DNA. Two sets of primers were used
for our methylation analysis (Table 1). One set was designed to
amplify the region of –256 to –92 relative to the transcriptional
start site, and the forward primer contained 3 CpG sites within the
specific region in the hMLH1 promoter reported to specifically
control hMLH1 expression (Deng et al, 1999). The other set of
primers was designed to amplify the region from –76 to +47 rela-
tive to the transcriptional start site, as previously described
(Yanagisawa et al, 2000). The promoter methylation was regarded
as positive when any of the 2 regions of the promoter was methy-
lated by PCR-based promoter methylation assay. The chemical
modification of unmethylated DNA with sodium bisulfite treat-
ment was performed essentially as described previously with
minor modification (Herman et al, 1996). 
RESULTS 
MSI status in gastric adenomas 
We found MSI-positive adenomas (MSI was demonstrated at more
than 2 of the 5 examined markers) in 15 (17%) of 86 gastric
adenomas. Representative examples of gastric adenomas and
carcinomas with MSI are shown in Figure 1A. 
The MSI status in the synchronous adenoma and carcinoma was
mostly the same, however, different MSI status was also found.
Among the 16 synchronous adenomas and carcinomas, 5 cases
showed MSI in both, and one case showed MSI only in the
adenoma (Table 2). 
Frameshift mutations of the target genes 
We analysed frameshift mutations by PCR amplification of the
region comprising the polynucleotide tract in the TGF-β RII gene,
BAX gene, hMSH3 gene, hMSH6 gene and IGFIIR gene in the
gastric adenomas and carcinomas with MSI. The frameshift muta-
tions of these 5 examined target genes were much less frequent in
the gastric adenomas than the gastric carcinomas (P = 0.019 by χ 2
test, Table 3). In the 15 MSI-positive gastric adenomas, 5 cases
showed no frameshift mutations from the 5 target genes.
Frameshift mutations in one gene were noted in 8 cases, 2 genes
in 1 case and 3 genes in 1 case. Among the 16 MSI-positive
gastric carcinomas, no frameshift mutation was noted in only one
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Table 1 PCR primers used for hMLH1 promoter methylation analysis 
Genomic positiona Primer setb Primer sequences Size (bp) Annealing temp (˚C) 
–256 ~ –92 U sense  AGGAAGAGTGGATAGTGATTTTTAAT 165 56 
antisense CAACCCCACCCTTCAACA 
–251 ~ –92 M sense  GAGCGGATAGCGATTTTTAAC 160 58 
antisense CAACCCCACCCTTCAACG 
–76 ~ +47 U sense  AGTTGAAGGAAGAATGTGAGTAT 124 61 
antisense CAAATAACCCCTACCACAAACA 
–75 ~ +46 M sense  GTTGAAGGAAGAACGTGAGTAC 122 63 
antisense GAATAACCCCTACCACGAACG 
aGenomic position is the location of the 5′ nucleotide of the sense primer in relation to the major transcriptional start site defined in the Genbank
accession number, U40960. bU, unmethylation-specific primer; M, methylation-specific primer. case. Frameshift mutation in one gene was noted in 4 cases, 2
genes in 7 cases, 3 genes in one case, 4 genes in 2 cases and all 5
genes in one case (Table 3). Increased frameshift mutations of
these 5 target genes in the carcinomas were also found in the cases
of synchronous adenomas and carcinomas (Table 2). All the
mutations in the adenoma were present in the coexistent carci-
noma and several additional mutations were present only in the
carcinoma (Figure 1B). 
Methylation status of hMLH1
The methylation status of hMLH1-promoter region was analysed
in 15 MSI-positive gastric adenomas, 20 MSI-negative gastric
adenomas, 16 MSI-positive gastric carcinomas and 22 MSI-negative
gastric carcinomas. The expression of hMLH1 was directly related
to the methylation status of the hMLH1 promoter (Table 3 and
Figure 1C). Among these 73 gastric tumours, 30 cases showed no
or decreased hMLH1 expression (13 MSI-positive adenomas, 1
MSI-negative adenoma, 14 MSI-positive carcinomas and 2 MSI-
negative carcinomas) and the remaining 43 cases showed intense
hMLH1 expression. In the 30 gastric tumours with no or decreased
hMLH1 expression, all showed hMLH1 promoter methylation; 26
cases showed methylation in both examined regions and 4 cases
showed methylation in only one region. Among the 43 gastric
tumours with strong hMLH1 expression, no methylation was
found in 34 cases, methylation in one region was found in 7 cases
and methylation in both regions were found in 2 cases. 
Expression of hMLH1 and hMSH2 in gastric adenomas 
Immunohistochemically, the hMLH1 protein was expressed in the
nucleus of normal and tumour tissues. In normal tissue, most of the
epithelial cells in the crypt, some stromal cells in the lamina
propria and many lymphocytes in the lymphoid follicle showed
nuclear staining. In tumour tissue, the intensity of expression was
different according to the MSI status. In 15 MSI-positive
adenomas, no hMLH1 expression in the tumour was observed in 7
cases and decreased expression was observed in 6 cases and the
remaining 2 cases showed intense nuclear staining (Figure 2). In
the 71 MSI-negative adenomas, 68 cases showed strong hMLH1
expression and 3 cases showed decreased expression in the
nucleus of the tumour cells. The expression pattern of hMLH1 in
MSI-positive gastric carcinomas was identical to that of gastric
adenomas. Among the 16 MSI-positive gastric carcinomas, 11
showed no hMLH1 expression, 3 cases showed decreased expres-
sion and the remaining 2 cases showed intense nuclear expression
(Figure 2). In contrast, 20 out of 22 MSI-negative carcinomas
showed intense nuclear expression of hMLH1 and the remaining 2
cases showed decreased expression. 
The expression of hMSH2 was also observed in normal and
tumour tissues. In normal tissue, the hMSH2 protein expression
was exclusively nuclear and was observed in the normal epithe-
lium of the mucous neck and in the germinal centre of the
lymphoid follicle. In tumour tissues, most of the cases showed
intense nuclear staining. No different expression pattern according
to the MSI status was observed. Intense nuclear staining was
demonstrated in 14 (93%) out of 15 MSI-positive tumours and in
68 (95%) out of 71 MSI-negative adenomas. Therefore, the
hMSH2 protein was expressed in most of the gastric carcinomas
irrespective of MSI status (Table 3). 
DISCUSSION 
In this study, we have analysed the expression of 2 members of
the MMR gene, hMLH1 and hMSH2, in gastric adenomas. We
report the striking difference in the expression of the hMLH1
gene according to the MSI status of the gastric adenomas. We
also report that the abnormal hMLH1 expression in gastric
adenoma is related to the methylation status of the hMLH1 gene
promoter. 
There have been many studies demonstrating MSI in gastric
adenomas and carcinomas (Rhyu et al, 1994; Lin et al, 1995;
Tamura et al, 1995; Chung et al, 1996; Semba et al, 1996; Wu et al,
1998; Kim et al, 1999). The MSI pathway begins with inactivation
of one of a group of genes responsible for DNA nucleotide
hMLH1 gene inactivation in gastric adenomas 1149
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Figure 1 Representative examples of microsatellite instability (A),
frameshift mutations of the 5 target genes (B), and promoter methylation of
hMLH1 gene (C) in the gastric adenomas and carcinomas. Case 9 had two
gastric adenomas, and cases 10, 11 and 12 had synchronous adenoma(s)
and carcinoma. In each case the adenoma (A), carcinoma (C) and
corresponding normal mucosa tissue (N) are shown. (A) MSI at BAT26 and
D2S123 was found in the adenoma #2 of case 9, adenoma and carcinoma of
case 10, adenoma #2 and carcinoma of case 11, and all the adenomas and
carcinoma of case 12. (B) Frameshift mutations at coding nucleotide repeats
of the 5 target genes in the gastric adenomas and carcinomas. Abnormal
bands with base insertions and deletions and indicated (arrowhead).
Frameshift mutations are found only in the cases of MSI-positive gastric
adenomas and carcinomas and additional mutations of hMSH3 and hMSH6
were found only in the carcinoma of case 11 and 12. (C) Methylation analysis
of hMLH1 promoter. All the cases with MSI showed product from the PCR
reaction with the methylation-specific primers. *, 100 bp ladder size marker;
U, PCR products from unmethylated DNA of hMLH1 promoter region; M,
PCR products from methylated DNA of hMLH1 promoter region mismatch repair, leading to extensive mutations in the repetitive
DNA sequences with low frequencies of allelic losses and rare
alteration of tumour DNA content (Loeb, 1994). Recent studies
have delineated that up to 90% of sporadic MSI-positive colorectal
carcinomas are due to the inactivation of hMLH1 gene, principally
transcriptional silencing, and the remainder are consistent with
inactivation of hMSH2 and hMLH1 by somatic mutation (Kane
et al, 1997; Herman et al, 1998; Thibodeau et al, 1998). Studies on
endometrial carcinomas also have shown a significant correlation
between MSI and hypermethylation of the hMLH1 gene promoter
(Esteller et al, 1998, 1999; Gurin et al, 1999; Simpkins et al,
1999). Highly frequent inactivation of hMLH1 gene has also been
reported in MSI-positive gastric carcinomas. Leung et al (1999)
found 100% hypermethylation of hMLH1 gene promoter in 11
MSI-positive gastric carcinomas and that 10 cases (90%) showed
complete absence of hMLH1 protein in the tumour cells. Other
studies demonstrated promoter methylation of hMLH1 gene in 3 of
5 (60%, Toyota et al, 1999), 14 of 18 (78%, Fleisher et al, 1999)
and 5 of 8 (63%, Suzuki et al, 1999) MSI-positive gastric carci-
nomas. In this study, we demonstrated loss of or decreased
hMLH1 expression in 13 of 15 (87%) MSI-positive gastric
adenomas and 14 of 16 (88%) MSI-positive gastric carcinomas.
We also found that all of those cases showed promoter hyperme-
thylation of the hMLH1 gene. These results suggest that transcrip-
tional silencing of the hMLH1 gene is the causative genetic event
both in the MSI-positive gastric adenomas and carcinomas and that
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Table 3 Immunohistochemical and genetic characteristics of MSI-positive gastric adenomas and carcinomas 
Variables Categories No. of MSI-positiveb adenomas (n = 15) No. of MSI-positive carcinomas (n = 16) P value 
hMSH2 expression absent 1 0 NSc
present 14 16 
hMLH1 expression absent 13 14 NS 
present 2 2 
hMLH1 promoter absent 1 1 NS 
methylation present 14 15 
Number of target genes 0.019 
with frameshift mutationsa
05 1  
18 4  
21 7  
31 1  
40 2  
50 1  
aframeshift mutations of the polynucleotide repeats of the TGFβ RII, BAX, hMSH3, hMSH6 and IGFIIR genes was analysed. bmicrosatellite instability-positive. 
cnot significant (P > 0.05). 
Table 2 Immunohistochemical and mutational profiles of synchronous MSI-positive gastric adenomas and carcinomas 
Type of tumour MSIa status Expression ofb Promoter    Frameshift mutationsc
hMSH2 hMLH1
methylation
TGFβ RII BAX hMSH3 hMSH6 IGFIIR of hMLH1
Case 10 
Adenoma + + – + 
Carcinoma + + – + +1/–1 
Case 11 
Adenoma #1 – ++   – 
Adenoma #2 + + – + –1/–1 +1/–1 –1/w 
Carcinoma + + – + –1/–1 –1/w –1/w –1/w –1/w 
Case 12 
Adenoma #1 + + – + –1/–1 
Adenoma #2 + + – + –1/w 
Adenoma #3 + + – + –1/–1 
Carcinoma + + – + –1/–1 –1/w 
Case 13 
Adenoma + + – + –2/–2 
Carcinoma + + – + –1/–2 +1/w 
Case 14 
Adenoma + + – + –1/w 
Carcinoma + + – + –1/–2 –1/w 
Case 15 
Adenoma + + – + –1/w 
Carcinoma – ++   – 
amicrosatellite instability; +, presence of MSI; –, no instability. b+, expression; –, absent or decreased expression. cNumber of inserted (+) or deleted (–) base
pairs on each allele; w, wild type. this inactivation is an early genetic event in the gastric carcinomas
with MSI-positive phenotype. 
In our MSI-positive gastric adenomas and carcinomas, most
of the tumour cells showed complete loss of hMLH1 expres-
sion, though some cases showed decreased hMLH1 expression
compared to the normal epithelial cells. This decreased hMLH1
expression was also found in some of the MSI-negative adenomas
and carcinomas. This incomplete loss of hMLH1 expression might
result from monoallelic hypermethylation or hypermethylation in
some proportion of the tumour cells, however differentiating
between monoallelic and biallelic inactivation is not always
possible in studies using human samples. Another possibility for
this incomplete hMLH1 inactivation lies in the methylation status
of the promoter. A recent study suggests that the area of promoter
methylation of the hMLH1 promoter region is critical for hMLH1
inactivation (Deng et al, 1999). In this experiment, we evaluated 2
different regions in the promoter, and one of which contained 3
CpG islands in the specific sites reported to control hMLH1 expres-
sion. In our gastric adenomas and carcinomas, some cases showed
different methylation status for these 2 regions. We could not,
however, find the specific relationship between the inactivation of
hMLH1 expression and region-specific promoter hypermethyla-
tion, because many cases with methylation in one of the 2 regions
also showed complete loss of hMLH1 expression. Inversely, some
rare cases of MSI-positive tumours (one adenoma and one carci-
noma) with hMLH1 promoter methylation in both regions showed
positive hMLH1 expression. From this experiment, however, we
could not explain the mechanisms of these rare exceptional cases.
To address this issue more precisely, the overall consequence of
changes after hypermethylation of hMLH1 promoter on gene
expression should be elucidated in the future. 
We demonstrated the same inactivation pattern of the 
MMR genes in the synchronous MSI-positive gastric adenomas
and carcinomas. Among the 16 synchronous gastric adenomas and
carcinomas, 5 cases showed MSI both in the adenomas and carci-
nomas. In these synchronous MSI-positive gastric adenomas and
carcinomas, both adenomas and carcinomas showed loss of
hMLH1 expression and promoter hypermethylation of hMLH1
gene. There were no differences in the number of markers with
MSI between the adenomas and carcinomas, however frameshift
hMLH1 gene inactivation in gastric adenomas 1151




Figure 2 Expression of hMLH1 in the gastric adenomas and carcinomas. Positive hMLH1 expression is noted in the nucleus of the gastric adenoma (A) and
carcinoma (B) cells. Decreased hMLH1 expression in the nucleus of gastric adenoma (C) and carcinoma (D) cells and complete loss of hMLH1 expression in
gastric adenoma (E) and carcinoma (F) cells are noted, whereas adjacent stromal cells and scattered lymphoid cells are positive for hMLH1 expression mutations of the target genes were more frequent in the coexistent
carcinomas. These findings are in accordance with our previous
results that more frameshift mutations of the genes containing
mononucleotide repeats were present in the carcinomas. The
results presented here support the hypothesis that the inactivation
of hMLH1 and MSI is an early event before or during the forma-
tion of the gastric adenomas and accumulated frameshift muta-
tions are late events related to the adenoma progression and
malignant transformation. 
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